Original publication in peer-reviewed journals:

    Google Scholar List

  1. Wiczling P, Evaluation of sequential Bayesian-based method development procedures for chromatographic problems involving one, two, and three analytes, Separation Science Plus 2018, 1, 63-75, 10.1002/sscp.201700037
  2. Estepp, JH; Wiczling, P; Moen, J; Kang, GL; Mack, JM; Liem, R; Panepinto, JA; Garg, U; Kearns, G; Neville, KA, Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure, British Journal Of Clinical Pharmacology, 2018, 84, 1478-1485, 10.1111/bcp.13426
  3. Bartosinska, E; Borsuk-De Moor, A; Siluk, D; Markuszewski, MJ; Wiczling, P, Ionization of tocopherols and tocotrienols in atmospheric pressure chemical ionization, Rapid Communications In Mass Spectrometry, 2018, 32, 919-927, 10.1002/rcm.8124
  4. Wiczling, P, Analyzing chromatographic data using multilevel modeling, Analytical And Bioanalytical Chemistry, 2018, 410, 3905-3915, 10.1007/s00216-018-1061-3
  5. Nguyen, LM; Singh, AP; Wiczling, P; Krzyzanski, W, Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats, Frontiers In Pharmacology, 2018, 9, 316-, 10.3389/fphar.2018.00316
  6. Borsuk-De Moor, A; Rypulak, E; Potrec, B; Piwowarczyk, P; Borys, M; Sysiak, J; Onichimowski, D; Raszewski, G; Czuczwar, M; Wiczling, P, Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock, Antimicrobial Agents And Chemotherapy, 2018, 62, -, 10.1128/AAC.02273-17
  7. Smuszkiewicz, P; Wiczling, P; Ber, J; Warzybok, J; Malkiewicz, T; Matysiak, J; Klupczynska, A; Trojanowska, I; Kokot, Z; Grzeskowiak, E; Krzyzanski, W; Bienert, A, Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients, Journal Of Pharmacokinetics and Pharmacodynamics, 2018, 45, 277-284, 10.1007/s10928-017-9564-7
  8. Wiczling, P; Daghir-Wojtkowiak, E; Mpanga, AY; Szczesny, D; Kaliszan, R; Markuszewski, MJ, How to model temporal changes in nontargeted metabolomics study? A Bayesian multilevel perspective, Journal Of Separation Science, 2017, 40, 4667-4676, 10.1002/jssc.201700918
  9. Mioduszewska, K; Dolzonek, J; Wyrzykowski, D; Kubik, L; Wiczling, P; Sikorska, C; Tonski, M; Kaczynski, Z; Stepnowski, P; Bialk-Bielinska, A, Overview of experimental and computational methods for the determination of the pKa values of 5-fluorouracil, cyclophosphamide, ifosfamide, imatinib and methotrexate, Trac-Trends In Analytical Chemistry, 2017, 97, 283-296, 10.1016/j.trac.2017.09.009
  10. Kubik, L; Wiczling, P; Kaliszan, R, pH-Gradient Liquid Chromatography: Fundamentals and Examples, Journal Of Aoac International, 2017, 100, 1590-1598, 10.5740/jaoacint.17-0205
  11. Borsuk, A; Woloszczuk-Gebicka, B; Bartkowska-Sniatkowska, A; Rosada-Kurasinska, J; Bienert, A; Wiczling, P, Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants, Journal Of Clinical Pharmacology, 2017, 57, 1194-1206, 10.1002/jcph.912
  12. Krzyzanski, W; Wiczling, P; Gebre, A, Age-structured population model of cell survival, Journal Of Pharmacokinetics And Pharmacodynamics, 2017, 44, 305-316, 10.1007/s10928-017-9520-6
  13. Daghir-Wojtkowiak, E; Wiczling, P; Waszczuk-Jankowska, M; Kaliszan, R; Markuszewski, MJ, Multilevel pharmacokinetics-driven modeling of metabolomics data, Metabolomics, 2017, 13, 31-, 10.1007/s11306-017-1164-4
  14. Szerkus, O; Struck-Lewicka, W; Kordalewska, M; Bartosinska, E; Bujak, R; Borsuk, A; Bienert, A; Bartkowska-Sniatkowska, A; Warzybok, J; Wiczling, P; Nasal, A; Kaliszan, R; Markuszewski, MJ; Siluk, D, HPLC-MS/MS method for dexmedetomidine quantification with Design of Experiments approach: application to pediatric pharmacokinetic study, Bioanalysis, 2017, 9, 395-406, 10.4155/bio-2016-0242
  15. Smuszkiewicz, P; Wiczling, P; Przybylowski, K; Borsuk, A; Trojanowska, I; Paterska, M; Matysiak, J; Kokot, Z; Grzeskowiak, E; Bienert, A, The pharmacokinetics of propofol in ICU patients undergoing long-term sedation, Biopharmaceutics & Drug Disposition, 2016, 37, 456-466, 10.1002/bdd.2028
  16. Szerkus, O; Jacyna, J; Wiczling, P; Gibas, A; Sieczkowski, M; Siluk, D; Matuszewski, M; Kaliszan, R; Markuszewski, MJ, Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures, Journal Of Chromatography B, 2016, 1029, 48-59, 10.1016/j.jchromb.2016.06.051
  17. Kubik, L; Wiczling, P, Quantitative structure-(chromatographic) retention relationship models for dissociating compounds, Journal Of Pharmaceutical And Biomedical Analysis, 2016, 127, 176-183, 10.1016/j.jpba.2016.02.050
  18. Wiczling, P; Bieda, K; Przybylowski, K; Hartmann-Sobczynska, R; Borsuk, A; Matysiak, J; Kokot, ZJ; Sobczynski, P; Grzeskowiak, E; Bienert, A, Pharmacokinetics and pharmacodynamics of propofol and fentanyl in patients undergoing abdominal aortic surgery – a study of pharmacodynamic drug-drug interactions, Biopharmaceutics & Drug Disposition, 2016, 37, 252-263, 10.1002/bdd.2009
  19. Wiczling, P; Bartkowska-Sniatkowska, A; Szerkus, O; Siluk, D; Rosada-Kurasinska, J; Warzybok, J; Borsuk, A; Kaliszan, R; Grzeskowiak, E; Bienert, A, The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors, Journal Of Pharmacokinetics And Pharmacodynamics, 2016, 43, 315-324, 10.1007/s10928-016-9474-0
  20. Estepp, JH; Melloni, C; Thornburg, CD; Wiczling, P; Rogers, Z; Rothman, JA; Green, NS; Liem, R; Brandow, AM; Crary, SE; Howard, TH; Morris, MH; Lewandowski, A; Garg, U; Jusko, WJ; Neville, KA, Pharmacokinetics and Bioequivalence of a Liquid Formulation of Hydroxyurea in Children With Sickle Cell Anemia, Journal Of Clinical Pharmacology, 2016, 56, 298-306, 10.1002/jcph.598
  21. Wiczling, P; Kaliszan, R, How Much Can We Learn from a Single Chromatographic Experiment? A Bayesian Perspective, Analytical Chemistry, 2016, 88, 997-1002, 10.1021/acs.analchem.5b03859
  22. Bartkowska-Sniatkowska, A; Bienert, A; Wiczling, P; Rosada-Kurasinska, J; Zielinska, M; Warzybok, J; Borsuk, A; Tibboel, D; Kaliszan, R; Grzeskowiak, E, Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients, Journal Of Clinical Pharmacology, 2016, 56, 109-115, 10.1002/jcph.577
  23. Kubik, L; Struck-Lewicka, W; Kaliszan, R; Wiczling, P, Simultaneous determination of hydrophobicity and dissociation constant for a large set of compounds by gradient reverse phase high performance liquid chromatography-mass spectrometry technique, Journal Of Chromatography A, 2015, 1416, 31-37, 10.1016/j.chroma.2015.09.003
  24. Wiczling, P; Kubik, L; Kaliszan, R, Maximum A Posteriori Bayesian Estimation of Chromatographic Parameters by Limited Number of Experiments, Analytical Chemistry, 2015, 87, 7241-7249, 10.1021/acs.analchem.5b01195
    25) Daghir-Wojtkowiak, E; Wiczling, P; Bocian, S; Kubik, L; Koslinski, P; Buszewski, B; Kaliszan, R; Markuszewski, MJ, Least absolute shrinkage and selection operator and dimensionality reduction techniques in quantitative structure retention relationship modeling of retention in hydrophilic interaction liquid chromatography, Journal Of Chromatography A, 2015, 1403, 54-62, 10.1016/j.chroma.2015.05.025

  25. Przybylowski, K; Tyczka, J; Szczesny, D; Bienert, A; Wiczling, P; Kut, K; Plenzler, E; Kaliszan, R; Grzeskowiak, E, Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery, Journal Of Pharmacokinetics And Pharmacodynamics, 2015, 42, 111-122, 10.1007/s10928-015-9404-6
  26. Bienert, A; Wawrzyniak, K; Wiczling, P; Przybylowski, K; Kokot, ZJ; Matysiak, J; Pachutko, A; Jozefowicz, M; Kusza, K; Grzeskowiak, E, Melatonin and Clonidine Premedication Has Similar Impact on the Pharmacokinetics and Pharmacodynamics of Propofol Target Controlled-Infusions, Journal Of Clinical Pharmacology, 2015, 55, 307-316, 10.1002/jcph.401
  27. Bienert, A, Płotek W, Wiczling P, Warzybok J, Borowska K, Buda K, Kuklińska K, Billert H, Kaliszan R, Grześkowiak E, The influence of age and dosage on the pharmacodynamics of dexmedetomidine in rabbits, Journal of Medical Science. 2014; 83, 108-115
  28. Bartkowska-Sniatkowska, A; Bienert, A; Wiczling, P; Owczarek, M; Rosada-Kurasinska, J; Grzeskowiak, M; Matysiak, J; Kokot, ZJ; Kaliszan, R; Grzeskowiak, E, Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries, Pharmacological Reports, 2014, 66, 821-829, 10.1016/j.pharep.2014.04.012
  29. Wiczling, P; Krzyzanski, W; Zychlinska, N; Lewandowski, K; Kaliszan, R, The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats, Biopharmaceutics & Drug Disposition, 2014, 35, 330-340, 10.1002/bdd.1902
  30. Wiczling, P; Liem, RI; Panepinto, JA; Garg, U; Abdel-Rahman, SM; Kearns, GL; Neville, KA, Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease, Journal Of Clinical Pharmacology, 2014, 54, 1016-1022, 10.1002/jcph.303
  31. Szerkus, O; Wolska, E; Struck-Lewicka, W; Siluk, D; Radwanska, A; Wiczling, P; Chorazewicz, J; Sznitowska, M; Markuszewski, MJ; Kaliszan, R, Development and validation of UHPLC method for the determination of cyclosporine A in biological samples, Biomedical Chromatography, 2014, 28, 802-809, 10.1002/bmc.3132
  32. Wiczling, P; Struck-Lewicka, W; Kubik, L; Siluk, D; Markuszewski, MJ; Kaliszan, R, The simultaneous determination of hydrophobicity and dissociation constant by liquid chromatography-mass spectrometry, Journal Of Pharmaceutical And Biomedical Analysis, 2014, 94, 180-187, 10.1016/j.jpba.2014.01.038
  33. Bienert, A; Plotek, W; Wiczling, P; Kostrzewski, B; Kaminska, A; Billert, H; Szczesny, D; Zaba, C; Tezyk, A; Buda, K; Bednarek, E; Kaliszan, R; Grzeskowiak, E, The influence of the time of day on midazolam pharmacokinetics and pharmacodynamics in rabbits, Pharmacological Reports, 2014, 66, 143-152, 10.1016/j.pharep.2013.06.009
  34. Bienert, A; Bartkowska-Sniatkowska, A; Wiczling, P; Rosada-Kurasinska, J; Grzeskowiak, M; Zaba, C; Tezyk, A; Sokolowska, A; Kaliszan, R; Grzeskowiak, E, Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children, Pharmacological Reports, 2013, 65, 107-121, 10.1016/S1734-1140(13)70969-1
  35. Struck, W; Wiczling, P; Waszczuk-Jankowska, M; Kaliszan, R; Markuszewski, MJ, New supervised alignment method as a preprocessing tool for chromatographic data in metabolomic studies, Journal Of Chromatography A, 2012, 1256, 150-159, 10.1016/j.chroma.2012.07.084
  36. Wiczling, P; Nasal, A; Kubik, L; Kaliszan, R, A new pH/organic modifier gradient RP HPLC method for convenient determination of lipophilicity and acidity of drugs as applied to established imidazoline agents, European Journal Of Pharmaceutical Sciences, 2012, 47, 1-5, 10.1016/j.ejps.2012.04.021
  37. Bienert, A; Wiczling, P; Grzeskowiak, E; Cywinski, JB; Kusza, K, Potential pitfalls of propofol target controlled infusion delivery related to its pharmacokinetics and pharmacodynamics, Pharmacological Reports, 2012, 64, 782-795, 10.1016/S1734-1140(12)70874-5
  38. Di Tullio, M; Maccallini, C; Ammazzalorso, A; Giampietro, L; Amoroso, R; De Filippis, B; Fantacuzzi, M; Wiczling, P; Kaliszan, R, QSAR, QSPR and QSRR in Terms of 3-D-MoRSE Descriptors for In Silico Screening of Clofibric Acid Analogues, Molecular Informatics, 2012, 31, 453-458, 10.1002/minf.201200001
  39. Wiczling, P; Bienert, A; Sobczynski, P; Hartmann-Sobczynska, R; Bieda, K; Marcinkowska, A; Malatynska, M; Kaliszan, R; Grzeskowiak, E, Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery, Pharmacological Reports, 2012, 64, 113-122, 10.1016/S1734-1140(12)70737-5
  40. Kaliszan, R; Wiczling, P, Gradient reversed-phase high-performance chromatography of ionogenic analytes, Trac-Trends In Analytical Chemistry, 2011, 30, 1372-1381, 10.1016/j.trac.2011.05.006
  41. Kaliszan, R; Wiczling, P; Markuszewski, MJ; Al-Haj, MA, Thermodynamic vs. extrathermodynamic modeling of chromatographic retention, Journal Of Chromatography A, 2011, 1218, 5120-5130, 10.1016/j.chroma.2011.05.077
  42. Perisic-Janjic, N; Kaliszan, R; Wiczling, P; Milosevic, N; Uscumlic, G; Banjac, N, Reversed-Phase TLC and HPLC Retention Data in Correlation Studies with in Silico Molecular Descriptors and Druglikeness Properties of Newly Synthesized Anticonvulsant Succinimide Derivatives, Molecular Pharmaceutics, 2011, 8, 555-563, 10.1021/mp100373d
  43. Bienert, A; Wiczling, P; Zaba, C; Zaba, Z; Wolc, A; Marciniak, R; Grzeskowiak, E; Kusza, K, Influence of demographic factors, basic blood test parameters and opioid type on propofol pharmacokinetics and pharmacodynamics in ASA I-III patients, Arzneimittel-Forschung-Drug Research, 2011, 61, 545-552,
  44. Bienert, A; Plotek, W; Zawidzka, I; Ratajczak, N; Szczesny, D; Wiczling, P; Kokot, ZJ; Matysiak, J; Grzeskowiak, E, Influence of Time of Day on Propofol Pharmacokinetics and Pharmacodynamics in Rabbits, Chronobiology International, 2011, 28, 318-329, 10.3109/07420528.2011.560317
  45. Hale, G; Rebello, P; Al Bakir, I; Bolam, E; Wiczling, P; Jusko, WJ; Vandemeulebroucke, E; Keymeulen, B; Mathieu, C; Ziegler, AG; Chatenoud, L; Waldmann, H, Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes, Journal Of Clinical Pharmacology, 2010, 50, 1238-1248, 10.1177/0091270009356299
  46. Krzyzanski, W; Wiczling, P; Lowe, P; Pigeolet, E; Fink, M; Berghout, A; Balser, S, Population Modeling of Filgrastim PK-PD in Healthy Adults Following Intravenous and Subcutaneous Administrations, Journal Of Clinical Pharmacology, 2010, 50, 101S-112S, 10.1177/0091270010376966
  47. Bienert, A; Kusza, K; Wawrzyniak, K; Grzeskowiak, E; Kokot, ZJ; Matysiak, J; Grabowski, T; Wolc, A; Wiczling, P; Regulski, M, Assessing circadian rhythms in propofol PK and PD during prolonged infusion in ICU patients, Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 289-304, 10.1007/s10928-010-9161-5
  48. Wiczling, P; Kaliszan, R, Retention time and peak width in the combined pH/organic modifier gradient high performance liquid chromatography, Journal Of Chromatography A, 2010, 1217, 3375-3381, 10.1016/j.chroma.2010.03.003
  49. Wiczling, P; Kaliszan, R, pH Gradient as a Tool for the Separation of Ionizable Analytes in Reversed-Phase High-Performance Chromatography, Analytical Chemistry, 2010, 82, 3692-3698, 10.1021/ac100023z
  50. Wiczling, P; Rosenzweig, M; Vaickus, L; Jusko, WJ, Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus, Journal Of Clinical Pharmacology, 2010, 50, 494-506, 10.1177/0091270009349376
  51. Wiczling, P; Ait-Oudhia, S; Krzyzanski, W, Flow Cytometric Analysis of Reticulocyte Maturation After Erythropoietin Administration in Rats, Cytometry Part A, 2009, 75A, 584-592, 10.1002/cyto.a.20736
  52. Wiczling, P; Lowe, P; Pigeolet, E; Ludicke, F; Balser, S; Krzyzanski, W, Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations, Clinical Pharmacokinetics, 2009, 48, 817-826, 10.2165/11318090-000000000-00000
  53. Wiczling, P; Waszczuk-Jankowska, M; Markuszewski, MJ; Kaliszan, R, The application of gradient reversed-phase high-performance liquid chromatography to the pK(a) and log k(w) determination of polyprotic analytes, Journal Of Chromatography A, 2008, 1214, 109-114, 10.1016/j.chroma.2008.10.085
  54. Wiczling, P; Kaliszan, R, Influence of pH on retention in linear organic modifier gradient RP HPLC, Analytical Chemistry, 2008, 80, 7855-7861, 10.1021/ac801093u
  55. Wiczling, P; Krzyzanski, W, Flow cytometric assessment of homeostatic aging of reticulocytes in rats, Experimental Hematology, 2008, 36, 119-127, 10.1016/j.exphem.2007.09.002
  56. Wiczling, P; Krzyzanski, W, Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model, Cytometry Part A, 2007, 71A, 460-467, 10.1002/cyto.a.20408
  57. Wiczling, P; Kawczak, P; Nasal, A; Kaliszan, R, Simultaneous determination of pK(a) and lipophilicity by gradient RP HPLC, Analytical Chemistry, 2006, 78, 239-249, 10.1021/ac0512103
  58. Markuszewski MJ, Wiczling P, Kaliszan R. Modele farmakokinetyczne. Farmakokinetyka podania doustnego leków oraz wielokrotne podanie leku. Farmacja Polska. 2006, 20.
  59. Kaliszan, M; Hauser, R; Kaliszan, R; Wiczling, P; Buczynski, J; Penkowski, M, Verification of the exponential model of body temperature decrease after death in pigs, Experimental Physiology, 2005, 90, 727-738, 10.1113/expphysiol.2005.030551
  60. Kaliszan, R; Wiczling, P, Theoretical opportunities and actual limitations of pH gradient HPLC, Analytical And Bioanalytical Chemistry, 2005, 382, 718-727, 10.1007/s00216-004-3023-1
  61. Wiczling, P; Markuszewski, MJ; Kaliszan, M; Galer, K; Kaliszan, R, Combined pH/organic solvent gradient HPLC in analysis of forensic material, Journal Of Pharmaceutical And Biomedical Analysis, 2005, 37, 871-875, 10.1016/j.jpba.2004.06.031
  62. Baczek, T; Wiczling, P; Marszall, M; Vander Heyden, Y; Kaliszan, R, Prediction of peptide retention at different HPLC conditions from multiple linear regression models, Journal Of Proteome Research, 2005, 4, 555-563, 10.1021/pr049780r
  63. Wiczling, P; Markuszewski, MJ; Kaliszan, M; Kaliszan, R, pH/Organic solvent double-gradient reversed-phase HPLC, ANALYTICAL CHEMISTRY, 2005, 77, 449-458, 10.1021/ac049092r Kaliszan, R; Wiczling, P; Markuszewski, MJ, pH gradient high-performance liquid chromatography: theory and applications, Journal Of Chromatography A, 2004, 1060, 165-175, 10.1016/j.chroma.2004.04.081
  64. Kaliszan, R; Markuszewski, MJ; Wiczling, P, Combined pH/organic modifier double gradient reversed-phase HPLC, Polish Journal Of Chemistry, 2004, 78, 1047-1056,
  65. Wiczling, P; Markuszewski, MJ; Kaliszan, R, Determination of pK(a) by pH gradient reversed-phase HPLC, Analytical Chemistry, 2004, 76, 3069-3077, 10.1021/ac049807q
  66. Markuszewski, MJ; Wiczling, P; Kaliszan, R, High-throughput evaluation of lipophilicity and acidity by new gradient HPLC methods, Combinatorial Chemistry & High Throughput Screening, 2004, 7, 281-289,
  67. Kaliszan, R; Wiczling, P; Markuszewski, MJ, pH gradient reversed-phase HPLC, Analytical Chemistry, 2004, 76, 749-760, 10.1021/ac034999v.